Screener
Ginkgo Bioworks DNA Reportable Segment — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
| Line item | Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|---|---|
| Research and development (1) | 30,433 | 31,065 | 60,538 | 79,735 |
| General and administrative (1) | 11,108 | 15,986 | 23,831 | 35,639 |
| Stock-based compensation (2) | 8,037 | 18,770 | 24,745 | 36,483 |
| Depreciation and amortization | 12,315 | 15,249 | 25,114 | 30,071 |
| Restructuring charges (3) | — | 3,566 | — | 8,032 |
| Carrying cost of excess space (net of sublease income) (4) | 14,233 | 12,413 | 30,074 | 24,088 |
| Merger and acquisition related expense (income) (5) | 1,106 | (3,617) | 1,106 | (4,535) |
| Other (income) expense, net (6) | (1,355) | (4,686) | 3,410 | (2,436) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ginkgo Bioworks's reportable segment — D&A?
- Ginkgo Bioworks (DNA) reported reportable segment — D&A of $12.32M in Q2 2026.
- What does reportable segment — D&A mean?
- This reflects the systematic allocation of the cost of tangible and intangible assets over their useful lives within a specific business segment. It provides visibility into the capital intensity of the segment and the ongoing investment required to maintain its operational infrastructure.
Ask your AI about Ginkgo Bioworks's reportable segment — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude